JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis

Eitemau Tebyg

• Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia
  gan: Antonioli, Elisabetta, et al.
  Cyhoeddwyd: (2010)
• JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera
  gan: Carobbio, Alessandra, et al.
  Cyhoeddwyd: (2009)
• The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia vera
  gan: Pieri, Lisa, et al.
  Cyhoeddwyd: (2009)
• Cytogenetics, JAK2 and MPL mutations in polycythemia vera, primary myelofibrosis and essential thrombocythemia
  gan: dos Santos, Leonardo Caires, et al.
  Cyhoeddwyd: (2011)
• JAK2(V617F) allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy
  gan: Silver, Richard T., et al.
  Cyhoeddwyd: (2010)